# Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation

> **NCT01615757** · PHASE3 · UNKNOWN · sponsor: **All India Institute of Medical Sciences** · enrollment: 180 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ara-c
- **DRUG:** Ara-c

## Key facts

- **NCT ID:** NCT01615757
- **Lead sponsor:** All India Institute of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2012-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01615757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01615757, "Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01615757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*